I think there is a strong chance that BIOYF / RX.V exceeds $5M in revenue for Q3. They had $1.5M of revenue in July, their large $627,512 international order shipped in August, and it is a big quarter for Insecticide Sales. I'll be happy if they just meet the one analyst expectation for Q3 of $4.6M in revenue and EPS of $0.08. However, I think there is a strong chance they blow that away.
The SwingTrade Portfolio was up 36.2% in 2014, 83.5% in 2013, and 510.9% since inception.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.